TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mental symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Clinically Significant Factor VIII Inhibitor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WURSS-21 QoL sub score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Demonstrating Improved MIO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pain Scores (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Consumption of Patient-Controlled and/or Rescue Analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Satisfaction of Postoperative Pain Management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body-fat and muscular percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cardiovascular capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of locoregional late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: All Cause Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Best Overall Responses (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sleep quality at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of participants with an occurrence of associated ADR
Endpoint domain: Adverse events/effects
Primary endpoint: Surface coverage pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a 1-log Reduction in HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to First Relapse of Any Mood Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Responders Measured by Clinical Global Impression (CGI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Tobacco Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Success (Score of 0 or 1) in Static Physician Global Assessment (sPGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC) of Ethinylestradiol (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC) of Levonorgestrel (LNG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximal concentration (Cmax) of Ethinylestradiol (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximal concentration (Cmax) of Levonorgestrel (LNG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnostic Consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Drug Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of comorbid events among hospitalized ADHF participants
Endpoint domain: Mortality/survival
Primary endpoint: Appropriate pacing indication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced hot flash frequency and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily insulin dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ocular safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dBP Change After 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sBP Change After 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma clearance of indocyanine green
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Plasma Concentration (Cmax) of drug lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Number of Observed Weekly Spontaneous Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Delivery room intubation or death
Endpoint domain: Mortality/survival
Primary endpoint: Geometric Mean Titers of Anti-Pertussis Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Pertussis Booster Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Tetanus and Anti-Diphtheria Booster Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of episodes of sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of metabolic crisis
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of hepatic failure
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant or > or = to Grade 3 CTCAE changes
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response in GBM tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of non-hematologic serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Uterine rupture incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Presence or absence of hypoglycemic unawareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of hypoglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin requirements in patients who did not become insulin independent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acceptability of WB-MRI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the curve (AUC) after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in Total Improvement Score (TIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in weight regain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endometrial receptivity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: subjective success rate (cure or improvement) of SUI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ankle Joint Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) - Chlorpromazine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) - 7-Hydroxy-Chlorpromazine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC(0-t)) - Chlorpromazine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC(0-t)) - 7-Hydroxy-Chlorpromazine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Performed a Thorough Skin Self-examination (SSE) in the Past 2 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: proportion of patients receiving influenza vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients Able to Complete 6 Cycles of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Meningococcal Antibody Titers ≥ 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relief of chemotherapy-induced myelosuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Hemoglobin A and S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum 17OHP Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement of subjective perception of dry mouth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in mean Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RBC exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum-tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of radial, linear and axial compression, bending and torsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of GLPG0634
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in ADHD-RS-IV score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pro-inflammatory cytokines plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-inflammatory cytokines plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall adverse events related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity and specificity of MRI diffusion in mediastinal masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing efficacy (clinical)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing efficacy (global)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Progression-free Survival (cPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity at 3 months
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation coefficient between DAS28-ESR and CDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of moist desquamation (grade 3) acute skin reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracerebral microdialysis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Composite Cognitive Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Favorable clinical outcomes assessed by Modified Rankin Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Sick-listed status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: one year all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: MACCE at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brachial artery blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of low-birth-weight newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Days of antibiotic therapy (DOTs)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent reduction in wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Discontinuations Due to Adverse Events Related to Ibalizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Time to occurrence of an IRIS event
Endpoint domain: Adverse events/effects
Primary endpoint: Prevision® survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Isometric Quadriceps Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Isokinetic Quadriceps Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Isometric Hip Abduction Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Isometric Hip Extension Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Isometric Hip External Rotation Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in youths' substance abuse frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in youths' delinquent behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in youths' mental health functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of initial LARC utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Emotion States
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Training adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Headache Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: modified Western Ontario and McMaster Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Levels of Meropenem or Ceftazidim Above MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Drug concentration in plasma at 12 hr after administration for Tipranavir (TPV) and Ritonavir (RTV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration time curve from 0-12 hours (AUC0-12h) for TPV and RTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Social and Occupational Functioning Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in percent BMI above the 95th percentile (%BMIp95)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of patients with obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for type of denture
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Comparison of fluid measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in HbA1c values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: acute renal injury on the scale pRIFLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: wound reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage excreted in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC, CL, lambda z, Cmax, t1/2, tmax and Vss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of liver-related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume and health of the future liver remnant (FLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cumulative dose of dopamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of B Cells at One Year Post-transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Adverse Events Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in serum creatinine after cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in urinary low molekular weight alpha 1 microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Daily urine output during the 72 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants Estimated to be Free of Progression at 12, 24, and 34 Months
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of grade 3-4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse reactions (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation of PCOS with metabolic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of PCOS with cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Adverse Events (AEs) per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Depressive Symptomatology (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of Secondary Dental Caries (Cavities)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weight loss response to bariatric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 2 diabetes remission after bariatric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Humeral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Earlier Relief of PDPH (in Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of remission after the first surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of recurrence after the first surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reported marijuana use (days of abstinence by week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of urine toxicology screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visceral fat levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual analogue score (VAS) for dysmenorrhea or chronic pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Overall and Intracranial Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neurodevelopmental follow up
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: total amount of morphine required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit as measured by biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician Knowledge About Sexual Health and Related Communication
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Clinician Self-Efficacy About Sexual Health Communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinician Communication About Sexual Health
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Presence of Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of FVIII Inhibitor Development
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the number of defecations per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Utility-weighted 90-day Modified Rankin Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood immune activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of implants per cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes